Last updated: 11/03/2018 15:21:43
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on clinicaltrials.gov.

An open-label Phase I drug-drug interaction study of ofatumumab with bendamustine for the treatment of subjects with indolent B-cell non-Hodgkin’s lymphoma

GSK study ID
113603
Clinicaltrials.gov ID
NCT01691807
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: An open-label Phase I drug-drug interaction study of ofatumumab with bendamustine for the treatment of subjects with indolent B-cell non-Hodgkin’s lymphoma
Trial description: The purpose of this study is to evaluate the potential drug-drug interactions between ofatumumab and bendamustine in subjects with previously untreated or relapsed indolent B-cell non-Hodgkin’s lymphoma (NHL).
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:

Pharmacokinetic measures of Cmax and Area Under the Curve by analysis of blood samples for the amount of each drug present at different timepoints.

Timeframe: 4 months

Secondary outcomes:

Measure the extent of the disease by CT scan or flow cytometry analysis

Timeframe: 14 months

Changes in vital signs and the number adverse events

Timeframe: 14 months

Interventions:
  • Drug: bendamustine
  • Drug: ofatumumab
    • Enrollment:
    30
    Primary completion date:
    2015-22-12
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Cancer, Neoplasms
    Product
    ofatumumab
    Collaborators
    Not applicable
    Study date(s)
    January 2013 to December 2015
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    18+ years
    Accepts healthy volunteers
    none
    • Subjects with previously untreated or relapsed indolent B-cell NHL requiring treatment. Indolent NHL is defined as small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), and follicular lymphoma (FL);
    • grades 1, 2, and 3A, defined according to WHO guidelines. Tumor verified to be CD20+ positive from a previous or current lymph node biopsy.
    • Subjects who failed to achieve a complete remission (CR) or partial remission (PR) or progressed within 6 months of last rituximab-containing therapy
    • Previous treatment with ofatumumab.
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Subjects with previously untreated or relapsed indolent B-cell NHL requiring treatment. Indolent NHL is defined as small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), and follicular lymphoma (FL); grades 1, 2, and 3A, defined according to WHO guidelines. Tumor verified to be CD20+ positive from a previous or current lymph node biopsy.
    • At least 4 weeks after previous anti-cancer chemotherapy, or radiotherapy treatment.
    • At least 12 weeks after previous anti-CD20 radioimmunotherapy, anti-CD20 antibody treatment, and non-anti-CD20 monoclonal antibody treatment.
    • Subjects who give consent to this study participation and sign the informed consent form.
    • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
    • Age greater than or equal to 18 years at informed consent.
    • A female subject is eligible to participate if she is of Non-childbearing potential or required to use a contraception method.
    • Male subjects with female partners of child-bearing potential must agree to use a contraception method.
    • Subjects must agree to use contraception until 12 months after the last dose of study drug.
    Exclusion criteria:
    • Subjects who failed to achieve a complete remission (CR) or partial remission (PR) or progressed within 6 months of last rituximab-containing therapy
    • Previous treatment with ofatumumab.
    • Prior bendamustine treatment not resulting in a complete remission and partial remission for at least 6 months.
    • Previous allogeneic stem cell transplant.
    • Previous autologous stem cell transplant.
    • High dose steroids greater than or equal to 100 mg prednisone/day (or equivalent) for greater than or equal to 7 consecutive days, given as concomitant medication, within 3 months prior to randomization. No more than 20 mg prednisone or equivalent daily at the time of randomization.
    • Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma as verified by biopsy confirmation.
    • Known central nervous system involvement by NHL.
    • Other past or current malignancy. Subjects who have been free of malignancy for at least 2 years, or have a history of definitively treated non-melanoma skin cancer, or successfully treated in situ carcinoma, are eligible.
    • Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, and active Hepatitis B or C. Prophylactic antibiotics to prevent recurrent of a prior infection (such as shingles, sinusitis or upper respiratory infection) is allowed.
    • Clinically significant cardiac disease as judged by the investigator, including unstable angina, acute myocardial infarction within 6 months of randomization, and uncontrolled congestive heart failure (CHF) or arrhythmia. Patients with a history of CHF or arrhythmia are eligible if their cardiac disease is well controlled on a stable medical regimen.
    • History of significant cerebrovascular disease or event with significant symptoms or sequelae (as judged by the investigator).
    • Significant concurrent, uncontrolled medical condition that in the opinion of the investigator contraindicates participation this study.
    • Positive serology for Hepatitis B (HB) defined as a positive test for Hepatitis B surface antigen (HBsAg). In addition, if negative for HBsAg but Hepatitis B core antibody (HBcAb) positive (regardless of Hepatitis B surface antibody [HBsAb] status), a HB DNA test will be performed and if positive the subject will be excluded. If HBV DNA is negative, the subject may be included but must undergo Hepatitis B virus (HBV) DNA monitoring (see Section 7.7.5). Prophylactic antiviral therapy may be initiated at the discretion of the investigator.
    • Current active liver or biliary disease (subjects with Gilbert’s syndrome or asymptomatic gallstones, liver metastases related to indolent NHL or otherwise stable chronic liver disease per investigator assessment, are eligible).
    • Known human immunodeficiency virus (HIV) positive.

      • Screening laboratory values:

      • platelets < 100 x 109/L (unless due to lymphoma involvement of the bone marrow)
      • neutrophils < 1.5 x 109/L (unless due to lymphoma involvement of the bone marrow)
      • serum creatinine > 1.5 times the institution’s upper limit of normal (ULN); subjects with a serum creatinine > 1.5 ULN will be eligible if the calculated creatinine clearance [Cockcroft, 1976] or creatinine clearance from a 24-hour urine collection is ≥ 40 mL/min
      • total bilirubin > 1.5 times ULN (unless due to liver involvement by lymphoma or Gilbert’s syndrome)
      • transaminases > 2 times ULN
    • Known or suspected hypersensitivity to ofatumumab, bendamustine, or mannitol.
    • Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half-lives or 4 weeks prior to Visit 1, whichever is longer or currently participating in any other interventional clinical study
    • Lactating women, women with a positive pregnancy test at Visit 1, or women (of childbearing potential) as well as men with partners of childbearing potential, who are not willing to use adequate contraception until 12 months after the last dose of study drug. Adequate contraception is defined in Section 8.1.

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    No study documents available.

    Results overview

    Study Results yet to be posted

    Recruitment status
    No longer a GSK study
    Actual primary completion date
    Not applicable
    Actual study completion date
    Not applicable

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website